Trial · NCT04052139
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Past Week Pain Severity | Low-dose Naltrexone | -0.97 | Standard Error 0.63 | units on a scale | |
| Change in Past Week Pain Severity | Gabapentin | -2.12 | Standard Error 0.38 | units on a scale | |
| Change in Past Week Pain Severity | Placebo | -1.85 | Standard Error 0.61 | units on a scale | |
| Change in Past Week Pain Interference | Low-dose Naltrexone | -1.73 | Standard Error 0.47 | units on a scale | |
| Change in Past Week Pain Interference | Gabapentin | -1.97 | Standard Error 0.64 | units on a scale | |
| Change in Past Week Pain Interference | Placebo | -2.14 | Standard Error 0.58 | units on a scale | |
| Change in Cold Pain Tolerance | Low-dose Naltrexone | -14.78 | Standard Error 7.61 | seconds | |
| Change in Cold Pain Tolerance | Gabapentin | -3.33 | Standard Error 4.56 | seconds | |
| Change in Cold Pain Tolerance | Placebo | -3.15 | Standard Error 6.89 | seconds | |
| Change in Percentage of Past Month Heavy Drinking Days | Low-dose Naltrexone | 3.07 | Standard Error 5.17 | % of change in heavy drinking days | |
| Change in Percentage of Past Month Heavy Drinking Days | Gabapentin | -4.22 | Standard Error 2.07 | % of change in heavy drinking days | |
| Change in Percentage of Past Month Heavy Drinking Days | Placebo | -4.63 | Standard Error 4.64 | % of change in heavy drinking days | |
| Change in CD4 Count | Low-dose Naltrexone | 15.85 | Standard Error 74.96 | cell/mm^3 | |
| Change in CD4 Count | Gabapentin | -106.47 | Standard Error 64.94 | cell/mm^3 | |
| Change in CD4 Count | Placebo | -52.13 | Standard Error 82.43 | cell/mm^3 | |
| Number of Participants With a Change in HIV Viral Load Suppression Status | Low-dose Naltrexone | 1 | Participants | ||
| Number of Participants With a Change in HIV Viral Load Suppression Status | Gabapentin | 0 | Participants | ||
| Number of Participants With a Change in HIV Viral Load Suppression Status | Placebo | 0 | Participants | ||
| Change in Biomarker IL-6 | Low-dose Naltrexone | -0.12 | Standard Error 0.19 | pg/ml | |
| Change in Biomarker IL-6 | Gabapentin | 0.04 | Standard Error 0.12 | pg/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04052139/results